Mr. Leigh Salvo reports
NOVADAQ RECEIVES COURT APPROVAL FOR ARRANGEMENT WITH STRYKER
The Ontario Superior Court of Justice has issued a final order approving Novadaq Technologies Inc.'s previously announced plan of arrangement under the
Canada Business Corporations Act, pursuant to which Stryker Corp. has agreed to acquire all of the issued and outstanding shares of Novadaq for $11.75 (U.S.) per share in cash.
The arrangement remains subject to the receipt of regulatory approvals under the Canadian Competition Act and U.S. Hart-Scott-Rodino and the satisfaction of certain other closing conditions customary in transactions of this nature. It is expected that the arrangement will close in the third quarter of 2017.
Shareholders that have questions regarding submitting their shares to the arrangement, including with respect to completing the letter of transmittal and election form, are asked to contact the depositary, Computershare Trust Company of Canada, at 1-800-654-6253 (toll-free in North America) or 1-514-982-7555 (collect outside North America), or by e-mail at email@example.com.
Novadaq's second quarter management's discussion and analysis and interim financial statements are expected to be released and filed on SEDAR and EDGAR on or about Friday, Aug. 11, 2017. The corporation will not host an earnings call to discuss second quarter results.
About Novadaq Technologies Inc.
Novadaq's global mission is to enable physicians with point-of-care imaging solutions that provide real-time clinically significant and actionable information to improve care quality and lower health care costs. Using Novadaq's SPY fluorescence imaging technology, physicians can personalize therapy and achieve optimal results through the precise visualization of blood flow in vessels, microvessels, tissue perfusion and critical anatomical structures during the course of treatment. SPY technology enables the delivery of personalized therapies and the achievement of the optimal results for each individual patient. More than 250 peer-reviewed publications demonstrate that the use of SPY technology will reduce postprocedure complication rates and the cost of care for a broad variety of surgical treatments for cancer, cardiovascular diseases and other conditions, helping to ensure that patients benefit from the very best possible treatment and outcome.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.